Last edition
News about "POTOMAC phase 3 trial"
IMFINZI from AstraZeneca has received US approval in combination with BCG for BCG-naïve, high-risk non-muscle-invasive bladder cancer, supported by Phase III POTOMAC trial data showing a 32 percent reduction in the risk of disease recurrence, progression, or death after one year of IMFINZI added to BCG vs. BCG alone.
POTOMAC Phase 3 Trial | 29/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members